SurModics — Investor Presentation (January 2022)
46 slides from SurModics's investor presentation, Jan 11, 2022
Slide 1: January 2022 Investor Presentation
January 2022 Gary MaharajPresident and CEOTim ArensSenior Vice President of Finance, IT and CFO 1 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 2: Safe Harbor
Some of the statements made during this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements about growth opportunities, expected revenue growth
Slide 3: We Are On A Mission: Simply Better
We Are On A Mission Simply Better. Because technology innovation is only as good as the confidence and adoption of its users. We believe simpler and better is the way to go to enable greater access to care by giving physicians the freedom to treat, anytime, anywhere. Simply Better. 3 © 2022 Surmodic
Slide 4: Simply Surmodics
Simply Surmodics. Growth Opportunity: High-growth, underpenetrated market opportunities serving current trends and future market needsCore Business: Strong source of operating cash fuels growth initiatives and commercial operationsStrong and growing businessesHigh ROIC Who are we? Learn more about u
Slide 5: Our Sights Are On Something Bigger
Our Sights Are On Something Bigger 5 Driven to do More Global Leader Secret Sauce Born to Innovate We Can Help The problems we address and the markets we serve are growing. We are directly relevant. The global leader in medical device coatings and in vitro diagnostics specialty reagents. We’ve been
Slide 6: What Matters Most
What Matters Most PatientsNo one should suffer from lifelong disability when the right treatment at the right time could have prevented it. CustomersLife-changing technology must move quickly into the hands of physicians everywhere. And it needs to happen fast.EmployeesSurmodics employees are person
Slide 7: Simply Better Solutions: Vascular Device Platforms
7 RADIAL ACCESS Simply Better Solutions DRUG-COATED BALLOONS We Innovate Learn more about our product portfolios Vascular Device Platforms THROMB0-EMBOLECTOMY CAUTION: SurVeil™, Sundance™ and Avess™ Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to invest
Slide 8: It's Not Enough To Be Different
DIFFERENT It’s Not Enough To Be Different DIFFERENCE First 5F radial sheathLongest length balloon cathetersBroke the trade-off between length & performance Stand-alone arterial mechanical device designed to clear chronic thrombo-embolic obstructionsGrab and go, on-table resolution First dual-action
Slide 9: Big Opportunities: Large, Underpenetrated Markets
Big Opportunities: We are Driven to Achieve PADPeripheral Artery Disease 0.8 M patients/year $0.4 BTAM <10%Penetrated PAO/DVTPeripheral Arterial Occlusion and Venous Thrombo-embolism 0.4 M patients/year $2.2 BTAM Market ~15%Penetrated PAD ATKPeripheral Artery Disease Above-the-knee 0.5 M patients/ye
Slide 10: Commercialization Strategies To Maximize Opportunities
Our Commercialization Strategies Enable Us To Maximize Our Opportunities In Significant And Growing Markets Direct Commercial ValidationFocused commitment from sales and marketingProduct development initiatives to expand portfolioAbility to expand and grow marketsEnhanced customer insights to inform
Slide 11: Committed To Driving Long-term Revenue Growth And Value Creation
Innovative product pipeline aimed at significant growth opportunitiesSeeking FDA approval for SurVeil™ DCB, which will address a $1.5B worldwide market opportunity through our commercial partner, Abbott(1)U.S. FDA clearances on five unique and differentiated thrombectomy and radial access products t
Slide 12: Our Fiscal 2022 Objectives Support Our Mission
12 Our Fiscal 2022 Objectives Support Our Mission. SurVeil™ Drug-Coated BalloonAchieve FDA PMA ApprovalSupport the commercialization efforts of our partner, Abbott VascularPounce™ Thrombectomy Platform and Sublime™ Radial Access platformsValidate commercial opportunityCapitalize on physician prefere
Slide 13: Drug-Coated Balloons
13 CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 14: SurVeil DCB: Third-Generation Design
GOALS for 3rd generation device are focused on addressing important clinical problemsCLINICAL – Similar therapeutic outcome with lower doseLower potential for complications Wider therapeutic windowTECHNOLOGICAL – Reduce Paclitaxel dose to 2.0 µg/mm²; improve uniformity of drug delivery/distributionB
Slide 15: SurVeil DCB Potential Significant Growth Catalyst
CAUTION: SurVeil™ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. Commercialization Of Our SurVeil™ DCB Has The Potential To Be A Significant Growth Catalyst 15 ~100,000 Above-the-knee Balloon Angioplasty Market – U.S.(1) Annual SFA
Slide 16: DCB Platform Extensions: Avess and Sundance
DCB Platform Extensions Avess™ AV Fistula DCB Sundance™ Below-The-Knee DCB First in human study results presented at 2020 VIVA conference by Dr. Andrew Holden, MBChBFreedom from revascularization at six months was greater than 90% for the 12 subjects (one re-intervention) with no AVF’s thrombosed. S
Slide 17: Poised, Positioned and Ready to Pounce
Poised, Positioned and Ready to Pounce 17 Poised: Two stand-alone, easy-to-use, highly effective mechanical thrombectomy devices; one for arterial use, the other for venous casesPositioned: Simple, effective designs make these devices ideal first-line treatments in their respective spacesPounce into
Slide 18: Pounce Arterial
18 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 19: Pounce Arterial Thrombo-embolectomy System
An Elegant Solution to a Complex Clinical Problem 19 Pounce™ Arterial Thrombo-embolectomy SystemDesigned to capture and remove organized and unorganized thrombo-emboli in the arterial peripheral vasculatureOff-the-shelf, stand-alone device – designed for use in time critical situations, with no addi
Slide 20: Large, Underpenetrated Market Opportunities In Clot Removal
Iliofemoral DVT patients Patients treated with mechanical thrombectomy 240,000 21,000 There Are Large, UnderpenetratedMarket Opportunities In Clot Removal 20 ARTERIAL CLOT REMOVAL U.S. MARKET Arterial$0.8 Billion30% Current PenetrationASP Ranges: $2K – $5K Patient figures and ASP ranges based on Man
Slide 21: Pounce Venous
21 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 22: There's a Lot More Life Left in These Limbs
DVT is a major health problem affecting >800,000 U.S. patients/year(1)Currently available technologies have shortcomings that limit broad-scale adoptionDelays in treatment can impact longer-term outcomes and elevate risk of post-thrombotic syndrome There’s a Lot More Life Left in These Limbs Clinica
Slide 23: Pounce Venous Thrombectomy: Patient First
Pounce Venous Thrombectomy: Patient First Because a vein is an organ. Self-adapting radial force: Basket maintains consistent circumferential force in veins ranging from 6-16 mm diameter Minimal hardware footprint: Rounded outer edge of the flexible basket is the only point where metal meets tissue
Slide 24: Pounce Venous Thrombectomy: Product Design
Pounce Venous Thrombectomy: Product Design Expand the basket using the handle dial. Activate the extraction screw Pull the catheter through the clot Dual-action Mechanical Thrombectomy separates clot from vein wall and extracts it at the point of collection—without removing the device from the patie
Slide 25: Sublime Radial Access
25 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 26: PVIs Rapidly Shifting to Office-Based Labs
Peripheral Vascular Interventions (PVIs) are rapidly shifting to office-based labs HOSPITAL(25.7%)Decrease in PVI ASC(12.9%)Decrease in PVI OBL305.7%Increase in PVI PVI SERVICES BY LOCATION Targeting the Greatest Needs and Largest Opportunities Majority of PVI procedure growth is focused below the k
Slide 27: Radial access benefits and references
1. As compared to transfemoral access in coronary procedures 2. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377:1409-20. 3. F
Slide 28: Sublime Radial Access Expands The Market
Sublime™ Radial Access Expands The Market By Enabling Radial Access Radial Access PTA Catheter U.S. Market Patient figures and ASP ranges based on Management Estimates as well as Public Health and Industry Data Patients treated with 018” PTA interventions 0.018” PTA (ATK+BTK)$50 Million8% Current Pe
Slide 29: Sublime Platform Can Get You There From Any Access Site
Sublime™ Platform Can Get You There From Any Access Site When a limb is on the line, physicians need to be confident they can tackle tough lesions. Why will SUBLIME products make you jump for joy? Sublime™ Guide Sheath beats the competition:Kink resistance – 60% better kink resistance1Radial Strengt
Slide 30: Medical Device Coatings
Medical Device Coatings 30 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 31: The Magic Is In The Coating
The Magic Is In The Coating CardiovascularRoyalty Rev = 25-35%CAGR = (1)-2% NeurologicalRoyalty Rev = 25-35%CAGR = 6-10% Peripheral VascularRoyalty Rev = 25-35%CAGR = 4-6% Structural HeartRoyalty Rev = <10%CAGR = 12–15% 25%-35% <10% ROYALTY REVENUE DISTRIBUTION1 Estimated Distribution of Surmodics’
Slide 32: A Stable Foundation For Future Growth
(1) Medical Device Coatings Over 150 license agreements among 100 customers30 U.S. patents issued; 64 International patents IssuedRoyalty rates for new licenses typically range from 2-3% for the device applicationProduct gross margins on the high end of medical device industry averages A Stable Foun
Slide 33: In Vitro Diagnostics (IVD)
33 In Vitro Diagnostics (IVD) © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 34: Leading Provider Of Components for IVD Tests and Microassays
Leading Provider Of Components for IVD Tests and Microassays In Vitro DiagnosticsOur components are used in test kits sold by the majority of the top ten global in vitro diagnostics companies> 1000 unique customers in several categories: Kit manufacturers, R&D institutions, Distributors and OEM’sPoi
Slide 35: Our Business Model Creates Long-lasting Partnerships
Our Business Model Creates Long-lasting Partnerships Development PartnersPartnering with customers during test development allows us to supply high performance critical raw material components for new immunoassay tests Focus on QualityOur focus on quality ensures streamlined manufacturing and consis
Slide 36: Continued Outstanding Results: IVD
Continued Outstanding Results 36 IN VITRO DIAGNOSTICS Growth: 4% 8% 14% Our IVD business is expected to continue to deliver mid-to-high single digit revenue growth annuallyStrong and growing customer base with broad portfolio of differentiated products Operating margin has improved each of the past
Slide 37: Surmodics Business Segments
37 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Surmodics Business Segments For the twelve months ended September 30, 2021 BUSINESSSEGMENTREVENUE IVDBUSINESS26% MEDICAL DEVICES74%
Slide 38: History of Strong Financial Performance
QUARTERLY REVENUE (MILLIONS) (1) (1) Includes $10.8 million related to the successful completion of a milestone in our SurVeil™ DCB agreement with Abbott ANNUAL REVENUE (MILLIONS) History of Strong Financial Performance 38 Funding our Growth Investments from Within: Our solid balance sheet and finan
Slide 39: Capital Allocation Priorities
Capital Allocation Priorities 39 Available Capital ($’s in Millions) September 30, 2021 Cash $31.2 Available-for-sale Investments $9.7 Revolving Line-of-Credit $15.0 Total $55.9 Available Capital Protect Liquidity & Balance Sheet Invest in Long-term Value Creation Our long-term capital allocation pr
Slide 40: Financial Guidance
Financial Guidance(As presented Nov. 10, 2021) 40 2022 Financial Guidance Long Term Objectives Total Revenue: $97 million to $101 million, including:$4.5 - $5.0 million of SurVeil™ DCB license fee revenue (compared with $16.0 million in fiscal 2021)(1) $2.0 - $2.5 million of Pounce™ and Sublime™ pro
Slide 41: Trademarks
41 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE, AVESS, TELEMARK, SERENE and the SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE and AVESS logos are trademarks of Surmodics Inc. and/or its affiliatesAll rights reserved. 01/22
Slide 42: Appendix
Appendix 42 © 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved.
Slide 43: Strategic Agreement with Abbott
Strategic Agreement with Abbott February 27, 2018 – Abbott and Surmodics Announced Agreement for Next-Generation Drug-Coated Balloon Development and CommercializationExclusive worldwide commercialization rights for SurVeil™ drug-coated balloon (DCB) for superficial femoral artery (SFA)Option to nego
Slide 44: SurVeil DCB - Impact to Financials
Based on the costs incurred and expected to be incurred from the execution of the Abbott agreement and not the actual cost from study inceptionPMA milestone revenue would be approximately $25M if the milestone is met in fiscal 2022We expect to recognize the entire $60.8 million associated with the l
Slide 45: Management Team
MANAGEMENT TEAM 45 Gary R. MaharajPresident and Chief Executive Officer (2010) Timothy J. ArensSenior Vice President of Finance and Information Technology and Chief Financial Officer (2007) Joseph J. Stich Senior Vice President of Human Resources and General Manager of In Vitro Diagnostics (2010) Go
Slide 46: Clinical Advisors
46 Clinical Advisors Ken Rosenfield, MD Chair Advisory Board — Interventional CardiologyMassachusetts General Hospital Gary Ansel, MD, FACC Clinical Advisor — Interventional CardiologyHealthcare Insights Marianne Brodmann MD, PhD Clinical Advisor— Interventional CardiologyDivision of Angiology Medic